Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR

• US 7,910,295 B2
• Filed: 11/14/2003
• Issued: 03/22/2011
• Est. Priority Date: 11/14/2002
• Status: Expired due to Fees

• Current Assignee: John Wayne Cancer Institute
• Original Assignee: John Wayne Cancer Institute
• Inventors: Takeuchi, Hiroya, Hoon, Dave S. B.
• Primary Examiner(s): Aeder; Sean E
• Application Number:
  US10/713,808
• Publication Number:
  US 20040265845A1
• Time in Patent Office: 2,685 Days
• Field of Search: 435/6, 435/7.1
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development

Abstract

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.

Claims

1. A method for melanoma prognosis, comprising:

(a) isolating nucleic acid from a sentinel lymph node (SLN) sample obtained from a first melanoma patient, wherein the SLN sample is histopathologically negative for melanoma cells;

(b) amplifying mRNA transcripts encoded by MAGE-A3, MART-1, GalNAcT and PAX3 marker genes, the mRNA transcripts being obtained from nucleic acid from the SLN sample obtained from the first melanoma patient;

(c) detecting levels of the mRNA transcripts encoded by the MAGE-A3, MART-1, GalNAcT and PAX3 marker genes; and

(d) comparing levels of mRNA transcripts encoded by the MAGE-A3, MART-1, GalNAcT and PAX3 marker genes in nucleic acid from an SLN sample obtained from a second melanoma patient to levels of mRNA transcripts encoded by the MAGE-A3, MART-1, GalNAcT and PAX3 marker genes in the nucleic acid from the SLN sample obtained from the first melanoma patient to predict metastatic melanoma recurrence, metastatic melanoma-free survival, overall survival, or a combination thereof, for the first melanoma patient, higher levels of the mRNA transcripts encoded by the MAGE-A3, MART-1, GalNAcT and PAX3 marker genes in the nucleic acid from the SLN sample obtained from the first melanoma patient indicating that the first melanoma patient has an increased probability of metastatic melanoma recurrence as compared to the probability of metastatic melanoma recurrence of the second melanoma patient, a decreased probability of metastatic melanoma-free survival as compared to the probability of metastatic melanoma-free survival of the second melanoma patient, or a decreased probability of overall survival as compared to the probability of overall survival of the second melanoma patient, and lower levels of the mRNA transcripts encoded by the MAGE-A3, MART-1, GalNAcT and PAX3 marker genes in the nucleic acid from the SLN sample obtained from the first melanoma patient indicating that the first melanoma patient has a decreased probability of metastatic melanoma recurrence as compared to the probability of metastatic melanoma recurrence of the second melanoma patient, an increased probability of metastatic melanoma-free survival as compared to the probability of metastatic melanoma-free survival of the second melanoma patient, or an increased probability of overall survival as compared to the probability of overall survival of the second melanoma patient.

2. The method of claim 1 wherein the nucleic acid is mRNA and the mRNA transcripts are amplified using real-time reverse transcriptase polymerase chain reaction (qRT-PCR).

3. The method of claim 1 wherein the SLN sample is paraffin-embedded (PE) or frozen.

4. The method of claim 1, wherein histopathology of the SLN sample is determined by hematoxylin and eosin staining or immunohistochemistry.

5. The method of claim 1, wherein the first melanoma patient'"'"'s prognosis is predicted for at least a three-year period following a removal of a primary tumor, sentinel lymphadenectomy (SLND), or both.

6. A method for melanoma prognosis, comprising:

(a) isolating nucleic acid from a sentinel lymph node (SLN) sample obtained from a first melanoma patient, wherein the SLN sample is histopathologically negative for melanoma cells;

(b) amplifying mRNA transcripts encoded by GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes, the mRNA transcripts being obtained from nucleic acid from the SLN sample obtained from the first melanoma patient;

(c) detecting levels of the mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes; and

(d) comparing levels of the mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes in nucleic acid from an SLN sample obtained from a second melanoma patient to levels of mRNA transcripts encoded by GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes in the nucleic acid from the SLN sample obtained from the first melanoma patient to determine whether the levels of mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-marker genes in the nucleic acid from the SLN sample obtained from the first melanoma patient are higher than the levels of mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes in the nucleic acid from the SLN sample obtained from the second melanoma patient.

7. The method of claim 6 wherein the nucleic acid is mRNA and the mRNA transcripts encoded by the marker genes are amplified using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).

8. The method of claim 6 wherein the SLN sample is paraffin-embedded (PE) or frozen.

9. The method of claim 6, wherein histopathology of the SLN sample is determined by hematoxylin and eosin staining or immunohistochemistry.

10. A method for melanoma prognosis comprising:

(a) isolating nucleic acid from a sentinel lymph node (SLN) sample obtained from a melanoma patient, wherein the SLN sample is histopathologically negative for melanoma cells;

(b) amplifying mRNA transcripts encoded by GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes by real-time reverse transcriptase polymerase chain reaction (qRT-PCR), the mRNA transcripts being obtained from nucleic acid from the SLN sample obtained from the melanoma patient; and

(c) quantifying each of the mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes by an mRNA copy number such that a positive copy number for any of the mRNA transcripts indicates a poorer prognosis for the patient than a copy number of zero.

11. A method for melanoma prognosis comprising:

(a) isolating nucleic acid from a sentinel lymph node (SLN) sample obtained from a melanoma patient, wherein the SLN sample is histopathologically negative for melanoma cells;

(b) amplifying mRNA transcripts encoded by GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes by real-time reverse transcriptase polymerase chain reaction (qRT-PCR), the mRNA transcripts being obtained from nucleic acid from the SLN sample obtained from the melanoma patient; and

(c) quantifying each of the mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3 and MART-1 marker genes by an mRNA copy number, each mRNA copy number being determined from a standard curve of known copy numbers for cDNA corresponding to each gene, a positive copy number for any of the mRNA transcripts indicating a poorer prognosis for the patient than a copy number of zero.

12. The method of claim 11 further comprising upstaging the prognosis for the patient if any copy number is greater than zero.

13. A method for melanoma prognosis in a patient, the method comprising:

(a) isolating nucleic acid from a sentinel lymph node (SLN) sample obtained from a melanoma patient, wherein the SLN sample is histopathologically negative for melanoma cells;

(b) amplifying mRNA transcripts encoded by GalNAcT, PAX3, MAGE-A3, and MART-1 marker genes by real-time reverse transcriptase polymerase chain reaction (qRT-PCR), the mRNA transcripts being obtained from nucleic acid from the SLN sample obtained from the melanoma patient; and

(c) quantifying levels of the mRNA transcripts encoded by the GalNAcT, PAX3, MAGE-A3, and MART-1 marker genes by an mRNA copy number such that an mRNA copy number greater than zero indicates a poorer prognosis for the melanoma patient than a copy number of zero.

14. The method of claim 13 further comprising upstaging the prognosis for the melanoma patient if the copy number is greater than zero.

15. The method of claim 13 wherein the nucleic acid is mRNA.

16. The method of claim 13 wherein the SLN sample is paraffin-embedded (PE) or frozen.

17. The method of claim 13 wherein histopathology of the SLN sample is determined by hematoxylin and eosin staining or immunohistochemistry.

18. The method of claim 13 wherein the patient'"'"'s prognosis is predicted for at least a three-year period following a removal of a primary tumor, sentinel lymphadenectomy (SLND), or both.